OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO
Updated: Jun 15, 2023
Ocular Therapeutix CEO Antony Mattessich describes the 12-month data his company has reported for its extended release TKI for wet AMD.
Also look for unique social pages for BiotechTV U.
10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.
Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.